# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 121-130 of 2216 results.
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma
Status: Enrolling by invitation
Last Changed: Dec 26, 2017
First Received: Dec 26, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Status: Unknown status
Last Changed: Dec 06, 2016
First Received: Nov 11, 2010
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): LBH589, Rituximab
Locations: Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Sacré-Cœur Hospital, Montreal, Quebec, Canada
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
Status: Unknown status
Last Changed: Jan 16, 2017
First Received: Jan 16, 2017
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): PL-doxorubicin and epirubicin
Locations: Fourth Hospital of Hebei Medical University, Shi Jiazhuang, Hebei, China
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Status: Terminated
Last Changed: Jul 10, 2014
First Received: Nov 08, 2011
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): MK2206
Locations: Institut Bergonié, Bordeaux, France
Centre Henri Mondor, Créteil, France
CHRU, Lille, France
Centre Leon Berard, Lyon, France
Institut Paoli Calmettes, Marseille, France
... and 9 other locations.
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Status: Unknown status
Last Changed: Nov 14, 2012
First Received: Aug 31, 2012
Disease(s): Relapsed or Refractory Diffuse Large B Cell Lymphoma
Intervention(s): 131I-rituximab
Locations: Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of
Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of
Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Status: Active, not recruiting
Last Changed: Aug 13, 2020
First Received: May 09, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): BGB-3111
Locations: Peking University Cancer Hospital, Beijing, Beijing, China
West China Hospital, Sichuan University, Chengdu, Chengdu, China
Zhengjiang Cancer hospital, Hangzhou, Hangzhou, China
Harbin Medical University Cancer Hospital, Haerbin, Helongjiang, China
Henan province cancer hospital, Zhengzhou, Henan, China
... and 7 other locations.
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Terminated
Last Changed: Jan 09, 2020
First Received: Sep 14, 2018
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): JHL1101, MabThera
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
Status: Recruiting
Last Changed: Mar 10, 2020
First Received: Jan 29, 2020
Disease(s): Lymphoma, B-Cell
Intervention(s): Rituximab Biosimilar, Pegylated Interferon α-2b
Locations: Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Treatment of Diffuse Large B Cell Lymphoma
Status: Unknown status
Last Changed: Dec 30, 2015
First Received: Sep 25, 2013
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Yangzhengxiaoji capsule combined with CHOP regimen, CHOP regimen
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 27, 2016
First Received: Apr 27, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): bendamustine, rituximab
Locations: Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of